EXAS: Exact Sciences Corp Company Profile & Statistics

About

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The company is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics. Exact Sciences currently has two of the brands in cancer diagnostics, Cologuard and Oncotype DX. Cologuard Test: This is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Oncotype DX: Genomic Health's first product, the 21-gene Oncotype DX breast cancer test is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early-stage patients.

Info & Links

CEO

Kevin T. Conroy

Headquarters

5505 ENDEAVOR LANE
MADISON, WI 53719, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

172

Employees

7,000

Exact Sciences Corp Statistics

Valuation Measures

Market Capitalization²

7.67B

Enterprise Value

9.64B

Enterprise Value/EBITDA(ttm)

270.62

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

3.33

Price to Book(mrq)

3.81

Price to Cash(ytd)

8.79

Profitability

Gross Margin(ttm)

69.67%

Operating Margin(ttm)

-5.72%

Profit Margin(ttm)

-36.53%

Return on Equity(ttm)

-5.29%

Return on Invested Capital(ttm)

-21.40%

Return on Assets(ttm)

-2.45%

Income Statement

Revenue(ttm)

2.76B

Revenue Per Share(ttm)

14.85

Gross Profit(ttm)

1.92B

EBITDA(ttm)³

35.62M

Net Income Available to Common(ttm)

-1.03B

Diluted EPS(ttm)

-5.57

Share Statistics

Beta (5Y Monthly)

1.24

52-Week Change

-34.26%

S&P 500 52-Week Change

5.42%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

185.76M

Dividend Yield

0.00%

Float⁴

182.56M

% Held by Insiders

1.36%

% Held by Institutions

88.82%

Balance Sheet

Total Cash(mrq)

1.04B

Total Cash Per Share(mrq)

5.59

Total Debt(mrq)

2.57B

Total Debt/Equity(mrq)

106.99%

Current Ratio(mrq)

2.15%

Quick Ratio(mrq)

1.93%

Book Value Per Share(mrq)

12.94

Cash Flow

Operating Cash Flow Per Share(ytd)

1.14

Free Cash Flow(ytd)

29.55M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

EXAS

Exact Sciences Corp

Exact Sciences Corp Profile